(CercleFinance.com) – J&J announces the initiation of a large-scale prospective study dedicated to evaluating in detail the efficacy and safety of Tremfya (guselkumab) as a treatment for psoriasis in non-white people. The idea is to generate additional data about this population.
Indeed, people of color are generally underrepresented in clinical studies, which produces a lack of scientific data concerning them and, by extension, constitutes an obstacle to optimal care for these patients.
When it comes to psoriasis, this redness-causing disease is sometimes less noticeable on darker skin tones, which can lead to misdiagnoses in people of color.
The J&J study therefore aims to address these health inequalities. So while Tremfya has a well-established safety and efficacy profile in a large population with PsO, there is still a pressing need for more data in people of color.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
